Peter Ashley Marks
Non-Executive Independent DirectorMr. Peter Ashley Marks, MBA, B.EC. LL.B. Grad. Dip. Comm. serves as Non-Executive Director of Evergold Minerals Limited (formerly known as Evergreen Lithium Limited) since January 21, 2022. He served as Chief Financial Officer at Accurus Aerospace Corp. since 2023 until 2024 and joined Accurus in 2023. He is Chairman of Newburyport Partners. He serves as a Principal and Consultant of Henslow Pty Ltd. Mr. Marks served as a Non-Executive Director of Elsight Limited since January 09, 2020 until October 01, 2021. Mr. Marks served as an Executive Director of Peregrine Corporate Limited from 2001 to August 2014. Previously, he served as an Adviser of Respiri Limited through October 20, 2010. From January 1992 until July 1994, Mr. Marks served as the Head of the Melbourne Companies Department at the Australian Stock Exchange. He served as Non-Independent Non-Executive Director at Nyrada Inc. since August 29, 2017 to August 1, 2022. During the period November 21, 2006 to October 20, 2011, Mr. Marks has also served as Executive Chairman of iSonea Ltd, formerly KarmelSonix Ltd. He was a Founding Director at Momentum Investment Group and Momentum Funds Management Pty Ltd. from January 1992 to July 1994. From September 1998 to March 2001, Mr. Marks was employed at KPMG Financial Advisory Services (Australia) Pty Limited, where he served as a Director and was responsible for Heading up the Equity Capital Markets Group in Melbourne. From December 1990 to December 1991, he served as a Director of Corporate Finance at Burdett Buckeridge & Young Ltd. from August 1998 to November 1990. From September 1998 until March 2001, Mr. Marks was employed by KPMG Corporate Finance Ltd (Australia), where he rose to Director and was responsible for Heading up the equity capital markets group in Melbourne. He has held senior corporate finance positions at Barings Securities Ltd. from July 1985 to July 1988. Mr. Marks served as an Associate Director at Merrill Lynch International (Australia) Limited. He was also employed at BBY Limited and Baring Securities Ltd. Mr. Marks has experience in corporate finance, specializing in capital raisings for listed and unlisted companies, underwritings, initial public listings and venture capital transactions with a focus on emerging technologies and life sciences, corporate advisory and investment banking. Furthermore, he has participated in public and private capital raisings. He has served as an Executive and Non-Executive Director of many entities which have been listed on the ASX, NASDAQ and AIM markets. He has been a Director and/or Chairman of several public companies. He served as an Executive Director of Select Vaccines Limited since December 31, 2001. Mr. Marks is also a Non-Executive Director of Terragenic International Ltd, (renamed Electriq~Global Ltd). He served as Non-Executive Chairman of Noxopharm Limited until April 2019 and serves as a Non-Executive Deputy Chairman since April 2019 and has been its Director since March 15, 2016. Mr. Marks serves as the Non-Executive Chairman of MicroFuze International Plc. He served as an Executive Chairman of Motopia Ltd. and served as its Director from December 18, 2001 to May 10, 2007. Mr. Marks served as an Executive Chairman of Respiri Limited from November 2006 to September 2010. He served as the Chairman of Armadale Capital Plc until July 21, 2016 and served as its Non-Executive Director until September 28, 2016. He has been a Non-Executive Director of RivusTV Limited since February 2007; MicroFuze International Plc since November 2005 and Non-Executive Independent Director of Alterity Therapeutics Limited (formerly known as Prana Biotechnology Limited) since July 29, 2005. He serves as Non-Executive Director of MicroFuze Americas, Inc. He served as a Non-Executive Director of Select Vaccines Limited from August 2005 to August 9, 2006. Mr. Marks served as a Non-Executive Director at Fluence Corporation Limited since May 12, 2015 until March 31, 2020. He possess experience in corporate advisory and investment banking. Over the course of his esteemed career, he has specialised in capital raising IPOs, cross border M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the U.S. and Israel. He serves as Non-Executive Director from March 4, 2026 and was Executive Director at Palisade Metals Ltd (formerly known as IRIS Metals Limited) since December 23, 2020 until March 04, 2026 and had been its Chairman of the Board since March 20, 2024 until March 04, 2026. He has been involved in a very broad range of transactions, with a special focus in the life sciences, biotechnology, medical technology and the high tech segments. He holds an M.B.A. degree from the Scottish School of Business at the University of Edinburgh. Mr. Marks received a Bachelor of Economics, Bachelor of Law/LLB and Graduate Diploma in Commercial Law from Monash University in Melbourne, Australia.
Positions
- Company NameAlterity Therapeutics LimitedStock CodeATHEPositionNon-Executive Independent DirectorColleagues
- DADavid A. StamlerCEO, MD & Director
- JBJulian BabarczyIndependent Non-Executive Chair
- AMAbby Macnish NivenCFO & Company Secretary
- RERudolph Emile TanziChief Scientific Advisor and Member of Research & Development Advisory Board
- SDSteven D. TargumChief Medical Advisor
- RCRobert ChernyHead of Research
- ISIra ShoulsonChairman of Research & Development Advisory Board
